{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:15:18Z","timestamp":1792012518948,"version":"4.4.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"crossref","award":["23-15-00471"],"award-info":[{"award-number":["23-15-00471"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"crossref","award":["23-15-00471"],"award-info":[{"award-number":["23-15-00471"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"crossref","award":["23-15-00471"],"award-info":[{"award-number":["23-15-00471"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"crossref","award":["23-15-00471"],"award-info":[{"award-number":["23-15-00471"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Poliomyelitis, preventable only through vaccination, remains a global health concern, with wild poliovirus transmission and the emergence of vaccine-derived polioviruses. The risk of further deterioration of the situation jeopardizes efforts to eradicate polio, which has been a long-term goal for the whole world. In this systematic review, an analysis of randomized clinical trials was carried out to comprehensively assess the immunogenicity and safety of various polio immunization methods in infants. Geometric mean neutralizing antibody titers (GMT) data collected after 28\u201331 days after immunization were used to calculate the geometric mean titer ratio (GMR), the analysis of which showed that both inactivated polio vaccine (IPV) and Sabin strain-based inactivated polio vaccine (sIPV) as primary vaccination induce high antibody rates. Average GMR rates (CI\u2009=\u20090.05) for the 3 types of polio were 83.08, 33.60, and 166.30 for IPV and 234.35, 44.04, and 163.13 for sIPV, with fractional IPV showing similar results. One or two doses of IPV were insufficient to induce protection levels of antibodies against type 2 poliovirus. The novel oral polio vaccine type 2 (nOPV2) and trivalent oral polio vaccine (tOPV) also demonstrated immunogenicity in establishing immunity comparable to the inactivated vaccine; the latter exhibited an average GMR of 50.75 for serotype 2. High antibody levels were also induced by combined vaccine schedules, with sIPV-sIPV-bOPV (GMR of 1,172.7 for type 1 and 887.6 for type 3) and IPV combinations with diphtheria-tetanus-whole-cell pertussis, hepatitis B and\n                    <jats:italic>Haemophilus influenzae<\/jats:italic>\n                    type b (351.2, 258.8, and 573.6 for the 3 types) or pentavalent rotavirus vaccine (354.6, 117.7, and 540.9 for the 3 types) establishing particularly high antibody levels. Analysis of adverse events presented all vaccines to be well-tolerated and safe, with a tendency for combination vaccines to have a higher frequency of local reactions and fever. While the studies presented a diverse landscape with some existing areas of concern, this review provides structured evidence supporting the safety and immunogenicity of existing polio vaccines, as well as highlighting the interchangeability of different vaccination approaches in infants. Future research should aim to provide detailed reporting of adverse events in order to facilitate more comprehensive assessment of vaccine immunogenicity and, therefore, efficacy.\n                  <\/jats:p>","DOI":"10.1186\/s12985-025-02977-3","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:19:38Z","timestamp":1761740378000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immunogenicity and safety of polio vaccines\u00a0in infants: a systematic review of randomized clinical trials"],"prefix":"10.1186","volume":"22","author":[{"given":"Roman P.","family":"Terekhov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem A.","family":"Svotin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria D.","family":"Korochkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasiya A.","family":"Khodyachikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail A.","family":"Varnavskiy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia N.","family":"Piniaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yury Yu.","family":"Ivin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry D.","family":"Zhdanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liubov I.","family":"Kozlovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Taldaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"2977_CR1","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1126\/science.2994218","volume":"229","author":"JM Hogle","year":"1985","unstructured":"Hogle JM, Chow M, Filman DJ. Three-dimensional structure of poliovirus at 2.9 \u00c5 resolution. Science. 1985;229:1358\u201365.","journal-title":"Science"},{"key":"2977_CR2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01560-13","author":"CP Burrill","year":"2013","unstructured":"Burrill CP, et al. Global RNA structure analysis of poliovirus identifies a conserved RNA structure involved in viral replication and infectivity. J Virol. 2013. https:\/\/doi.org\/10.1128\/jvi.01560-13.","journal-title":"J Virol"},{"key":"2977_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/1941874414533352","volume":"4","author":"MM Mehndiratta","year":"2014","unstructured":"Mehndiratta MM, Mehndiratta P, Pande R. Poliomyelitis. Historical facts, epidemiology, and current challenges in eradication. Neurohospitalist. 2014;4:223\u20139.","journal-title":"Neurohospitalist"},{"key":"2977_CR4","unstructured":"Kenneth R, George R, Sherris JC (eds) Sherris medical microbiology: an introduction to infectious diseases. (McGraw-Hill, New York, 2004)."},{"key":"2977_CR5","unstructured":"Poliomyelitis. (polio). https:\/\/www.who.int\/health-topics\/poliomyelitis"},{"key":"2977_CR6","unstructured":"GPEI-Wild Poliovirus. https:\/\/polioeradication.org\/wild-poliovirus\/"},{"key":"2977_CR7","unstructured":"GPEI-The Vaccines. https:\/\/polioeradication.org\/about-polio\/the-vaccines\/"},{"key":"2977_CR8","unstructured":"GPEI-Polio this week. https:\/\/polioeradication.org\/about-polio\/polio-this-week\/"},{"key":"2977_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/S0140-6736(17)32442-X","volume":"391","author":"M Zaffran","year":"2018","unstructured":"Zaffran M, McGovern M, Hossaini R, Martin R, Wenger J. The polio endgame: securing a world free of all polioviruses. Lancet. 2018;391:11\u20133.","journal-title":"Lancet"},{"key":"2977_CR10","unstructured":"GPEI-Variant Poliovirus (cVDPV). https:\/\/polioeradication.org\/about-polio\/the-virus\/vaccine-derived-polioviruses\/"},{"key":"2977_CR11","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.vaccine.2009.02.071","volume":"27","author":"P Minor","year":"2009","unstructured":"Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine. 2009;27:2649\u201352.","journal-title":"Vaccine"},{"key":"2977_CR12","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","volume":"59","author":"OM Kew","year":"2005","unstructured":"Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch M. A. VACCINE-DERIVED POLIOVIRUSES AND THE ENDGAME STRATEGY FOR GLOBAL POLIO ERADICATION*. Annu Rev Microbiol. 2005;59:587\u2013635.","journal-title":"Annu Rev Microbiol"},{"key":"2977_CR13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1586\/14760584.2015.1001750","volume":"14","author":"M Patel","year":"2015","unstructured":"Patel M, Zipursky S, Orenstein W, Garon J, Zaffran M. Polio endgame: the global introduction of inactivated polio vaccine. Expert Rev Vaccines. 2015;14:749\u201362.","journal-title":"Expert Rev Vaccines"},{"key":"2977_CR14","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1016\/S0140-6736(15)00237-8","volume":"386","author":"RW Sutter","year":"2015","unstructured":"Sutter RW, et al. Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial. Lancet. 2015;386:2413\u201321.","journal-title":"Lancet"},{"key":"2977_CR15","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0140-6736(16)00703-0","volume":"388","author":"EJ Asturias","year":"2016","unstructured":"Asturias EJ, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet. 2016;388:158\u201369.","journal-title":"Lancet"},{"key":"2977_CR16","first-page":"504","volume":"221","author":"JF Modlin","year":"2020","unstructured":"Modlin JF, Chumakov K. Sabin strain inactivated polio vaccine for the polio endgame. J Infect Dis. 2020;221:504\u20135.","journal-title":"J Infect Dis"},{"issue":"35","key":"2977_CR17","doi-asserted-by":"publisher","first-page":"934","DOI":"10.15585\/mmwr.mm6535a3","volume":"65","author":"LM Hampton","year":"2016","unstructured":"Hampton LM. Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine \u2014 Worldwide, 2016. MMWR Morb Mortal Wkly Rep. 2016; 65(35):934-8. https:\/\/doi.org\/10.15585\/mmwr.mm6535a3","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2977_CR18","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S0264-410X(02)00584-4","volume":"21","author":"MM Khan","year":"2003","unstructured":"Khan MM, Ehreth J. Costs and benefits of polio eradication: a long-run global perspective. Vaccine. 2003;21:702\u20135.","journal-title":"Vaccine"},{"key":"2977_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.vaccine.2010.10.026","volume":"29","author":"RJ Duintjer Tebbens","year":"2010","unstructured":"Duintjer Tebbens RJ, et al. Economic analysis of the global polio eradication initiative. Vaccine. 2010;29:334\u201343.","journal-title":"Vaccine"},{"key":"2977_CR20","unstructured":"GPEI-Vaccine Derived Poliovirus count. https:\/\/polioeradication.org\/circulating-vaccine-derived-poliovirus-count\/"},{"key":"2977_CR21","unstructured":"Polio eradication. strategy 2022\u20132026: delivering on a promise. https:\/\/www.who.int\/publications\/i\/item\/9789240031937"},{"key":"2977_CR22","doi-asserted-by":"publisher","unstructured":"The PRISMA. 2020 statement: an updated guideline for reporting systematic reviews | The BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"key":"2977_CR23","doi-asserted-by":"publisher","unstructured":"PROSPERO: An International Register of Systematic Review Protocols. Medical Reference Services Quarterly: Vol 38, No 2 - Get Access. https:\/\/www.tandfonline.com\/doi\/full\/https:\/\/doi.org\/10.1080\/02763869.2019.1588072","DOI":"10.1080\/02763869.2019.1588072"},{"key":"2977_CR24","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. | Wiley Online Books. https:\/\/onlinelibrary.wiley.com\/doi\/book\/10.1002\/9780470712184"},{"key":"2977_CR25","doi-asserted-by":"crossref","unstructured":"RoB 2. A revised tool for assessing risk of bias in randomised trials | the BMJ (2019). https:\/\/www.bmj.com\/content\/366\/bmj.l4898","DOI":"10.1136\/bmj.l4898"},{"key":"2977_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias visualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021;12:55\u201361.","journal-title":"Res Synth Methods"},{"key":"2977_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1162\/qss_a_00177","volume":"3","author":"M Thelwall","year":"2022","unstructured":"Thelwall M, Sud PS. 1900\u20132020: growth in articles, abstracts, countries, fields, and journals. Quant Sci Stud. 2022;3:37\u201350.","journal-title":"Quant Sci Stud"},{"key":"2977_CR28","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ van Eck","year":"2010","unstructured":"van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84:523\u201338.","journal-title":"Scientometrics"},{"key":"2977_CR29","doi-asserted-by":"publisher","unstructured":"van Eck NJ, Waltman L. Text mining and visualization using VOSviewer. Preprint at https:\/\/doi.org\/10.48550\/arXiv.1109.2058 (2011).","DOI":"10.48550\/arXiv.1109.2058"},{"key":"2977_CR30","unstructured":"A smart local. moving algorithm for large-scale modularity-based community detection | Eur Phys J B (2013). https:\/\/link.springer.com\/article\/10.1140\/epjb\/e2013-40829-0#citeas"},{"issue":"7","key":"2977_CR31","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/S1473-3099(17)30177-9","volume":"17","author":"L Rivera","year":"2017","unstructured":"Rivera L, et al. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial. Lancet Infect Dis. 2017;17(7):745\u201353.","journal-title":"Lancet Infect Dis"},{"key":"2977_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ijid.2023.01.020","volume":"130","author":"G Feng","year":"2023","unstructured":"Feng G, et al. Safety, immunogenicity, and lot-to-lot consistency of a multidose Sabin strain-based inactivated polio vaccine: a phase III, randomized, blinded, positive-control clinical trial in infants aged 2 months. Int J Infect Dis. 2023;130:20\u20137.","journal-title":"Int J Infect Dis"},{"key":"2977_CR33","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.vaccine.2016.02.010","volume":"34","author":"R Li","year":"2016","unstructured":"Li R, et al. Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China. Vaccine. 2016;34:1436\u201343.","journal-title":"Vaccine"},{"key":"2977_CR34","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1080\/21645515.2017.1288769","volume":"13","author":"J Qiu","year":"2017","unstructured":"Qiu J, et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non-inferiority clinical trial. Hum Vaccin Immunother. 2017;13:1359\u201368.","journal-title":"Hum Vaccin Immunother"},{"key":"2977_CR35","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/infdis\/jiaa770","volume":"226","author":"MR Capeding","year":"2022","unstructured":"Capeding MR, et al. Safety and immunogenicity of a new inactivated polio vaccine made from Sabin strains: a randomized, double-blind, active-controlled, phase 2\/3 seamless study. J Infect Dis. 2022;226:308\u201318.","journal-title":"J Infect Dis"},{"key":"2977_CR36","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1016\/j.vaccine.2020.02.066","volume":"38","author":"X S\u00e1ez-Llorens","year":"2020","unstructured":"S\u00e1ez-Llorens X, et al. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15\u201318 months. Vaccine. 2020;38:3780\u20139.","journal-title":"Vaccine"},{"key":"2977_CR37","doi-asserted-by":"publisher","first-page":"6274","DOI":"10.1016\/j.vaccine.2020.07.042","volume":"38","author":"S Yan","year":"2020","unstructured":"Yan S, et al. Immunogenicity and safety of different sequential schedules of Sabin strain-based inactivated poliovirus vaccination: a randomized, controlled, open-label, phase IV clinical trial in China. Vaccine. 2020;38:6274\u20139.","journal-title":"Vaccine"},{"key":"2977_CR38","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.vaccine.2021.01.027","volume":"39","author":"R Jiang","year":"2021","unstructured":"Jiang R, et al. Immunogenicity and safety of the inactivated poliomyelitis vaccine made from Sabin strains in a phase IV clinical trial for the vaccination of a large population. Vaccine. 2021;39:1463\u201371.","journal-title":"Vaccine"},{"key":"2977_CR39","doi-asserted-by":"publisher","first-page":"905634","DOI":"10.3389\/fimmu.2022.905634","volume":"13","author":"X Sun","year":"2022","unstructured":"Sun X, et al. Immunogenicity and safety of concomitant administration of the Chinese inactivated poliovirus vaccine with the diphtheria-tetanus-acellular pertussis (DTaP) vaccine in children: a multicenter, randomized, non-inferiority, controlled trial. Front Immunol. 2022;13:905634.","journal-title":"Front Immunol"},{"key":"2977_CR40","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(22)02397-2","volume":"401","author":"K Zaman","year":"2023","unstructured":"Zaman K, et al. Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial. Lancet. 2023;401:131\u20139.","journal-title":"Lancet"},{"key":"2977_CR41","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(23)02844-1","volume":"403","author":"M Ochoge","year":"2024","unstructured":"Ochoge M, et al. Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <\u20095 years and lot-to-lot consistency of the immune response to nOPV2 in infants in the gambia: a phase 3, double-blind, randomised controlled trial. Lancet. 2024;403:1164\u201375.","journal-title":"Lancet"},{"key":"2977_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1473-3099(23)00519-4","volume":"24","author":"L Rivera Mej\u00eda","year":"2024","unstructured":"Rivera Mej\u00eda L, et al. Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic. Lancet Infect Dis. 2024;24:275\u201384.","journal-title":"Lancet Infect Dis"},{"key":"2977_CR43","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1080\/21645515.2020.1745593","volume":"16","author":"R Tang","year":"2020","unstructured":"Tang R, et al. A phase \u2161, randomized, controlled trial to evaluate the safety and immunogenicity of a Sabin strain-based inactivated polio vaccine. Hum Vaccin Immunother. 2020;16:2641\u20138.","journal-title":"Hum Vaccin Immunother"},{"key":"2977_CR44","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1016\/j.ijid.2011.10.002","volume":"16","author":"J Cadorna-Carlos","year":"2012","unstructured":"Cadorna-Carlos J, Vidor E, Bonnet M-C. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis. 2012;16:e110-6.","journal-title":"Int J Infect Dis"},{"key":"2977_CR45","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/INF.0000000000003975","volume":"42","author":"L Sanchez","year":"2023","unstructured":"Sanchez L, et al. Immunogenicity and safety of a hexavalent DTwP-IPV-HB-PRP\u2009~\u2009T vaccine versus separate DTwP-HB-PRP\u2009~\u2009T, bOPV, and IPV vaccines administered at 2, 4, 6 months of age concomitantly with rotavirus and Pneumococcal conjugate vaccines in healthy infants in Thailand. Pediatr Infect Dis J. 2023;42:711\u20138.","journal-title":"Pediatr Infect Dis J"},{"key":"2977_CR46","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.jiac.2019.11.012","volume":"26","author":"T Nakayama","year":"2020","unstructured":"Nakayama T, et al. Immunogenicity and safety of a DTaP-IPV\/Hib pentavalent vaccine given as primary and booster vaccinations in healthy infants and toddlers in Japan. J Infect Chemother. 2020;26:651\u20139.","journal-title":"J Infect Chemother"},{"key":"2977_CR47","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1080\/21645515.2016.1239670","volume":"13","author":"Y Li","year":"2017","unstructured":"Li Y, et al. Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV\/Hib) administered in Chinese infants. Hum Vaccin Immunother. 2017;13:588\u201398.","journal-title":"Hum Vaccin Immunother"},{"key":"2977_CR48","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3346\/jkms.2016.31.9.1383","volume":"31","author":"JH Kang","year":"2016","unstructured":"Kang JH, et al. The immunogenicity and safety of a combined DTaP-IPV\/\/Hib vaccine compared with individual DTaP-IPV and Hib (PRP\u2009~\u2009T) vaccines: a randomized clinical trial in South Korean infants. J Korean Med Sci. 2016;31:1383.","journal-title":"J Korean Med Sci"},{"key":"2977_CR49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ijid.2005.10.014","volume":"11","author":"TY Lin","year":"2007","unstructured":"Lin TY, et al. A fully liquid diphtheria\u2013tetanus\u2013five component acellular pertussis\u2013inactivated poliomyelitis\u2013Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants. Int J Infect Dis. 2007;11:129\u201336.","journal-title":"Int J Infect Dis"},{"key":"2977_CR50","doi-asserted-by":"publisher","first-page":"801","DOI":"10.47102\/annals-acadmedsg.V36N10p801","volume":"36","author":"FS Lim","year":"2007","unstructured":"Lim FS, Han H-H, Jacquet J-M, Bock HL. Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine. Ann Acad Med Singapore. 2007;36:801\u20136.","journal-title":"Ann Acad Med Singapore"},{"key":"2977_CR51","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/21645515.2016.1225639","volume":"13","author":"SK Lalwani","year":"2017","unstructured":"Lalwani SK, et al. Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV\/Hib in Indian infants. Hum Vaccin Immunother. 2017;13:120\u20137.","journal-title":"Hum Vaccin Immunother"},{"key":"2977_CR52","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/21645515.2017.1294294","volume":"13","author":"T Vesikari","year":"2017","unstructured":"Vesikari T, et al. Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV\/Hib combination vaccine in comparison with the licensed Infanrix hexa. Hum Vaccin Immunother. 2017;13:1505\u201315.","journal-title":"Hum Vaccin Immunother"},{"key":"2977_CR53","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2324538","volume":"20","author":"S Chen","year":"2024","unstructured":"Chen S, et al. A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China. Hum Vaccin Immunother. 2024;20:2324538.","journal-title":"Hum Vaccin Immunother"},{"key":"2977_CR54","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S1473-3099(15)00059-6","volume":"15","author":"S Iqbal","year":"2015","unstructured":"Iqbal S, et al. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US vaccine adverse event reporting system, 2000\u201312. Lancet Infect Dis. 2015;15:1175\u201382.","journal-title":"Lancet Infect Dis"},{"key":"2977_CR55","volume":"3","author":"H Hogenesch","year":"2012","unstructured":"Hogenesch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol. 2012;3:406.","journal-title":"Front Immunol"},{"key":"2977_CR56","unstructured":"GPEI-History of Polio. https:\/\/polioeradication.org\/about-polio\/history-of-polio\/"},{"issue":"Suppl 1","key":"2977_CR57","doi-asserted-by":"publisher","first-page":"A85","DOI":"10.1016\/j.vaccine.2022.03.013","volume":"41","author":"A Voorman","year":"2023","unstructured":"Voorman A, et al. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine. Vaccine. 2023;41(Suppl 1):A85\u201392.","journal-title":"Vaccine"},{"key":"2977_CR58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4103\/0974-777X.77298","volume":"3","author":"DA Skibinski","year":"2011","unstructured":"Skibinski DA, Baudner BC, Singh M, O\u2019Hagan DT. Combination vaccines. J Glob Infect Dis. 2011;3:63.","journal-title":"J Glob Infect Dis"},{"key":"2977_CR59","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s13312-012-0063-z","volume":"49","author":"M Jl","year":"2012","unstructured":"Jl M. Inequity in childhood immunization in india: a systematic review. Indian Pediatr 2012;49:203-23.","journal-title":"Indian Pediatr"},{"key":"2977_CR60","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1097\/INF.0000000000004478","volume":"43","author":"M Toizumi","year":"2024","unstructured":"Toizumi M, Takamatsu M, Toda K, Horikoshi Y. Progresses toward polio eradication in Asian countries: its history and Japan\u2019s contributions. Pediatr Infect Dis J. 2024;43:e347-53.","journal-title":"Pediatr Infect Dis J"},{"key":"2977_CR61","first-page":"37","volume":"6","author":"R Reverberi","year":"2008","unstructured":"Reverberi R. The statistical analysis of immunohaematological data. Blood Transfus. 2008;6:37\u201345.","journal-title":"Blood Transfus"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02977-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02977-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02977-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:04:38Z","timestamp":1761743078000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02977-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2977"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02977-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6913898\/v1","asserted-by":"object"}]},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"348"}}